FEV | FEV (ETS oncogene family) | Cancer-related genes Disease related genes Transcription factors
| | | | | Tissue enhanced |
FOLH1 | Folate hydrolase (prostate-specific membrane antigen) 1 | Cancer-related genes Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins
| | | | | Tissue enhanced |
FOXA1 | Forkhead box A1 | Cancer-related genes Transcription factors
| | | | | Tissue enhanced |
GABRG3 | Gamma-aminobutyric acid (GABA) A receptor, gamma 3 | FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
GATA2 | GATA binding protein 2 | Cancer-related genes Disease related genes Transcription factors
| | | | | Tissue enhanced |
GCSAML | Germinal center-associated, signaling and motility-like | | | | | | Tissue enhanced |
GJC3 | Gap junction protein, gamma 3, 30.2kDa | Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
GLB1L3 | Galactosidase, beta 1-like 3 | | | | | | Tissue enhanced |
GLIS1 | GLIS family zinc finger 1 | Transcription factors
| | | | | Tissue enhanced |
GUCY2D | Guanylate cyclase 2D, membrane (retina-specific) | Disease related genes Enzymes Potential drug targets Predicted membrane proteins
| | | | | Tissue enhanced |
HIST1H2AD | Histone cluster 1, H2ad | | | | | | Tissue enhanced |
HIST1H2AE | Histone cluster 1, H2ae | | | | | | Tissue enhanced |
HIST1H2BF | Histone cluster 1, H2bf | Plasma proteins
| | | | | Tissue enhanced |
HIST1H4E | Histone cluster 1, H4e | Cancer-related genes Disease related genes
| | | | | Tissue enhanced |
HIST2H2AA3 | Histone cluster 2, H2aa3 | | | | | | Tissue enhanced |
HIST2H2BF | Histone cluster 2, H2bf | | | | | | Tissue enhanced |
IRX4 | Iroquois homeobox 4 | Plasma proteins Transcription factors
| | | | | Tissue enhanced |
ISL1 | ISL LIM homeobox 1 | Transcription factors
| | | | | Tissue enhanced |
KCNH6 | Potassium voltage-gated channel, subfamily H (eag-related), member 6 | Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enhanced |
LRRC24 | Leucine rich repeat containing 24 | Predicted membrane proteins
| | | | | Tissue enhanced |
LY6G6D | Lymphocyte antigen 6 complex, locus G6D | Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
MESP1 | Mesoderm posterior 1 homolog (mouse) | Transcription factors
| | | | | Tissue enhanced |
MKX | Mohawk homeobox | Transcription factors
| | | | | Tissue enhanced |
MYH3 | Myosin, heavy chain 3, skeletal muscle, embryonic | Disease related genes Plasma proteins
| | | | | Tissue enhanced |
NLRP9 | NLR family, pyrin domain containing 9 | | | | | | Tissue enhanced |
NPPC | Natriuretic peptide C | Predicted secreted proteins Transporters
| | | | | Tissue enhanced |
OPRK1 | Opioid receptor, kappa 1 | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
OR51E1 | Olfactory receptor, family 51, subfamily E, member 1 | G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
P2RX2 | Purinergic receptor P2X, ligand-gated ion channel, 2 | Disease related genes Predicted membrane proteins
| | | | | Tissue enhanced |
PCP4 | Purkinje cell protein 4 | | | | | | Tissue enhanced |
PDE11A | Phosphodiesterase 11A | Disease related genes Enzymes Potential drug targets Predicted secreted proteins
| | | | | Tissue enhanced |
PMEPA1 | Prostate transmembrane protein, androgen induced 1 | Cancer-related genes Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
PRDM8 | PR domain containing 8 | Transcription factors
| | | | | Tissue enhanced |
PRKG2 | Protein kinase, cGMP-dependent, type II | Enzymes
| | | | | Tissue enhanced |
RAB3B | RAB3B, member RAS oncogene family | | | | | | Tissue enhanced |
RFPL1 | Ret finger protein-like 1 | | | | | | Tissue enhanced |
RP11-1102P16.1 | Uncharacterized protein | | | | | | Tissue enhanced |
RP11-481A20.11 | Protein LOC101060662 | | | | | | Tissue enhanced |
RPE65 | Retinal pigment epithelium-specific protein 65kDa | Disease related genes Enzymes Potential drug targets
| | | | | Tissue enhanced |
SALL3 | Spalt-like transcription factor 3 | Plasma proteins Transcription factors
| | | | | Tissue enhanced |
SELE | Selectin E | Cancer-related genes Candidate cardiovascular disease genes CD markers Plasma proteins Predicted membrane proteins
| | | | | Tissue enhanced |
SHISA9 | Shisa family member 9 | Predicted membrane proteins
| | | | | Tissue enhanced |
SHROOM1 | Shroom family member 1 | | | | | | Tissue enhanced |
SLC14A1 | Solute carrier family 14 (urea transporter), member 1 (Kidd blood group) | Blood group antigen proteins Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
SLC15A2 | Solute carrier family 15 (oligopeptide transporter), member 2 | Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
SLC16A8 | Solute carrier family 16 (monocarboxylate transporter), member 8 | Plasma proteins Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
SLC2A12 | Solute carrier family 2 (facilitated glucose transporter), member 12 | Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
SLC30A4 | Solute carrier family 30 (zinc transporter), member 4 | Plasma proteins Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
SLC35F4 | Solute carrier family 35, member F4 | Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
SPDEF | SAM pointed domain containing ETS transcription factor | Transcription factors
| | | | | Tissue enhanced |